Global Leading Market Research Publisher QYResearch announces the release of its latest report “Pulmonary Fibrosis Biomarker – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Pulmonary Fibrosis Biomarker market, including market size, share, demand, industry development status, and forecasts for the next few years.
As pulmonologists, clinical laboratory directors, and pharmaceutical R&D executives confront the diagnostic challenges posed by Idiopathic Pulmonary Fibrosis (IPF) and progressive fibrosing Interstitial Lung Disease (ILD) , the strategic integration of Pulmonary Fibrosis Biomarker testing has emerged as a transformative solution for Precision Diagnostics in Pulmonology. The core clinical friction is unambiguous: conventional diagnostic modalities—including high-resolution computed tomography (HRCT) and pulmonary function testing—provide essential structural and functional assessments but lack the molecular sensitivity to reliably predict disease progression, monitor therapeutic response, or stratify patients for clinical trial enrichment. Accurate forced vital capacity (FVC) measurement requires proper patient technique and specialized coaching, and serial HRCT imaging carries cumulative radiation exposure concerns . IPF Prognostic Testing utilizing blood-based Lung Fibrosis Detection biomarkers resolves this tension through objective, quantifiable molecular indicators—including Krebs von den Lungen-6 (KL-6), matrix metalloproteinase-7 (MMP-7), surfactant proteins A and D (SP-A/SP-D), and CCL18—that reflect epithelial injury, fibroblast activation, and extracellular matrix remodeling with minimal patient burden. The broader context underscores this urgency: global IPF prevalence continues to rise, with estimates ranging from 14 to 43 cases per 100,000 population in regions such as India, where annual case growth of 5-7% further highlights the need for advanced diagnostic tools . For C-suite executives navigating value-based healthcare transitions and pharmaceutical leaders pursuing targeted therapy development, Pulmonary Fibrosis Biomarker platforms represent not merely incremental diagnostic enhancement but a fundamental enabler of Personalized Medicine for Fibrosis.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6089180/pulmonary-fibrosis-biomarker
The global market for Pulmonary Fibrosis Biomarker was estimated to be worth US$ 4,601 million in 2025 and is projected to reach US$ 6,112 million by 2032, growing at a steady CAGR of 4.2% from 2026 to 2032. Pulmonary Fibrosis Biomarkers are measurable molecular or cellular indicators found in blood, bronchoalveolar lavage fluid, or lung tissue that reflect the extent of fibrosis, disease activity, inflammation, or therapeutic response in the lungs. Key biomarkers include KL-6, SP-A/SP-D, MMP-7, CCL18, and YKL-40, which are involved in epithelial injury, fibroblast activation, and extracellular matrix remodeling. These biomarkers play a critical role in the early diagnosis, disease monitoring, prognosis prediction, and personalized treatment of pulmonary fibrosis, particularly Idiopathic Pulmonary Fibrosis (IPF) .
Market Dynamics: Regulatory Milestones and Clinical Validation Driving Biomarker Adoption
The 4.2% CAGR projected through 2032 is underpinned by structural demand drivers spanning diagnostic innovation, regulatory advancement, and pharmaceutical R&D imperatives. Foremost among catalysts is the accelerating clinical validation and regulatory recognition of Pulmonary Fibrosis Biomarker panels for IPF Prognostic Testing. In December 2025, the FDA’s Center for Drug Evaluation and Research accepted the PROLIFIC Risk Score’s Letter of Intent into its Biomarker Qualification Program—marking the first time an IPF biomarker has achieved this milestone . The PROLIFIC panel, incorporating SP-D, CA-125, Tenascin C (TNC), BLC/CXCL13, and sICAM-1, assesses the likelihood of disease progression (≥10% FVC decline, lung transplant, or death within one year), representing a paradigm shift toward objective, blood-based Precision Diagnostics in Pulmonology .
A second powerful driver is the expanding body of clinical evidence establishing the prognostic utility of established Lung Fibrosis Detection markers. Analysis of the ISABELA trials—the largest IPF cohort studied to date with 1,280 patients—demonstrated that patients with ≥10% annual FVC decline had significantly higher median baseline MMP-7 levels (5.5 µg/L versus 4.2 µg/L). Furthermore, patients with baseline MMP-7 ≥5.2 μg/L and/or CCL18 ≥75.2 μg/L exhibited substantially increased mortality risk, with those having both biomarkers elevated facing the poorest prognosis . This robust clinical validation positions Pulmonary Fibrosis Biomarker testing as an essential tool for Personalized Medicine for Fibrosis, enabling risk-stratified patient management and targeted therapeutic intervention.
Tariff and Supply Chain Considerations:
The 2025 U.S. tariff adjustments have introduced meaningful recalibration within the Pulmonary Fibrosis Biomarker supply chain, particularly affecting imported immunoassay reagents, specialized monoclonal antibodies, and diagnostic instrumentation components. These trade measures have accelerated regionalization of manufacturing and strategic diversification of raw material sourcing, with leading IVD manufacturers evaluating near-shoring strategies to mitigate tariff exposure. Concurrently, evolving regulatory frameworks—including FDA guidance on biomarker qualification and EU IVDR compliance requirements—continue to shape product development timelines and market entry strategies for Interstitial Lung Disease diagnostic platforms.
Technology Segmentation: ELISA Dominance and Emerging Molecular Platforms
The Pulmonary Fibrosis Biomarker market exhibits clear segmentation across detection methodologies, reflecting varying throughput requirements, sensitivity thresholds, and clinical application contexts:
- ELISA (Enzyme-Linked Immunosorbent Assay): Dominant technology platform for IPF Prognostic Testing, offering robust quantitative performance, established laboratory workflows, and broad availability of validated kits for KL-6, MMP-7, SP-A/SP-D, and related markers. This segment represents the largest share of current Pulmonary Fibrosis Biomarker testing volume, driven by widespread clinical laboratory adoption and favorable cost-per-test economics.
- RT-PCR (Real-Time Polymerase Chain Reaction): Addresses applications requiring high analytical sensitivity and multiplexing capability, particularly for gene expression profiling and MUC5B promoter polymorphism (rs35705950) genotyping. The rs35705950 T allele frequency varies significantly by ethnicity—approximately 40.2% in White populations versus 5.7% in Asian populations—underscoring the importance of population-specific Precision Diagnostics in Pulmonology .
- Immunohistochemistry (IHC): Complements serum-based testing through tissue localization of fibrotic and inflammatory markers in lung biopsy specimens, supporting histopathological confirmation of Interstitial Lung Disease subtypes.
Competitive Landscape and Strategic Implications
The Pulmonary Fibrosis Biomarker market is segmented as below:
Key Manufacturers Profiled:
Fujirebio, Roche, Bio-Techne, Myriad RBM, Thermo Fisher Scientific, RayBiotech, Beijing Kemei Biotechnology, Fosun Diagnostics, Mike Biotech.
Segment by Type
- ELISA
- RT-PCR
- Immunohistochemistry
Segment by Application
- Hospital
- Diagnostic Laboratories
- Other
Strategic Implications:
The competitive ecosystem is characterized by established IVD leaders leveraging deep immunoassay expertise and specialized biomarker innovators. Fujirebio maintains leadership in KL-6 testing, with extensive clinical validation across Asian and European Interstitial Lung Disease populations. Roche and Thermo Fisher Scientific leverage broad instrumentation installed bases and integrated laboratory workflow solutions. Bio-Techne and Myriad RBM differentiate through multiplexed protein profiling capabilities supporting pharmaceutical clinical trial applications .
For C-suite executives and investors, the strategic implication is clear: Pulmonary Fibrosis Biomarker represents a clinically validated, regulatory-advancing diagnostic segment with sustained demand from global Precision Diagnostics in Pulmonology imperatives, aging demographic tailwinds, and pharmaceutical Personalized Medicine for Fibrosis development. As FDA biomarker qualification pathways mature and clinical evidence supporting IPF Prognostic Testing accumulates, Lung Fibrosis Detection platforms delivering robust analytical performance and seamless laboratory integration will capture disproportionate share within this structurally supported market.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
